Results 21 to 30 of about 38,997 (290)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation, 2019
Aims/Introduction We investigated the difference in efficacy and safety between discontinuation and maintaining of sulfonylurea when adding a sodium–glucose cotransporter 2 inhibitor.
Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi, Hideaki Miyoshi   +14 more
doaj   +1 more source

Unintentional sulfonylurea toxicity due to a drug–drug interaction: a case report

BMC Research Notes, 2018
Background Sulfonylureas are widely used for type 2 diabetes mellitus, but these medications carry a risk of hypoglycemia. Drug–drug interactions that inhibit sulfonylurea metabolism and thus increase systemic exposure can cause unintentional ...
Keith Gunaratne, Emily Austin, Peter E. Wu   +2 more
doaj   +1 more source

Cantu syndrome–associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms [PDF]

, 2018
The complex disorder Cantu syndrome (CS) arises from gainof-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively. Recent reports indicate that such mutations
Grange, Dorothy K., Hanson, Alex, Josifova, Dragana, McClenaghan, Conor, Nichols, Colin G., Roessler, Helen I., Sala-Rabanal, Monica, van Haaften, Gijs   +7 more
core   +2 more sources

The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]

, 2014
INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core   +2 more sources

Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study [PDF]

Endocrinology and Metabolism
Background Inconsistent results have been reported regarding the association between the use of antidiabetic drugs and the clinical outcomes of coronavirus disease 2019 (COVID-19). This study aimed to investigate the effect of antidiabetic drugs on COVID-
Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee   +5 more
doaj   +1 more source

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor II [PDF]

, 1994
Glimepiride is a novel sulfonylurea for the treatment of type II-diabetic patients exhibiting different receptor binding kinetics to β-cell membranes with 8–9-fold higher koff rate and 2.5–3-fold higher kon rate compared to glibenclamide (see ...
Aguilar-Bryan, Aguilar-Bryan, Ashcroft, Bayley, De Weille, Ehle, Galizzi, Geisen, Geisen, Glossmann, Glossmann, Hogg, Hollemans, Kramer, Kramer, Kramer, Kramer, Martyr, Müller, Nelson, Nelson, Niki, Ozanne, Panten, Pomerantz, Repke, Schmid-Antomarchi, Schwanstecher, Skeer, Wessel   +29 more
core   +1 more source

MODY3 in the child with type 2 diabetes mellitus phenotype: case report

Сахарный диабет, 2013
MODY is a heterogeneous group of diseases that stem from certain genetic mutations and are characterized by beta-cell dysfunction, early clinical onset (before the age of 25) and autosomal dominant inheritance.
Tamara Leonidovna Kuraeva, Elena Alexandrovich Sechko, Irina Alexandrovna Eremina, O N Ivanova, Sergey Alexandrovich Prokof’ev   +4 more
doaj   +1 more source

Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same KCNJ11 variants

Endocrine Regulations, 2020
Objective. Mutations of the KCNJ11 gene are the most common cause of the permanent neonatal diabetes mellitus (PNDM). Majority of people with KNCJ11-PNDM have a de-novo mutation.
Stanik Juraj, Barak Lubomir, Dankovcikova Adriana, Valkovicova Terezia, Skopkova Martina, Gasperikova Daniela   +5 more
doaj   +1 more source

Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis

Medicina, 2022
Background and objectives: In the last couple of years, pharmacological management of patients with type 2 diabetes mellitus (T2DM) have been markedly renewed. The aim of this study was to analyse the changes in prescribing patterns of antidiabetic drugs
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, Csaba Lengyel, Péter Kempler, István Wittmann   +6 more
doaj   +1 more source

Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus [PDF]

, 2006
Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Balkau, Forst, Haffner, Haffner, Hedblad, Howard, Huupponen, Langenfeld, Maseri, Matthews, Morrow, Nissen, Paice, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Pfützner, Ridker, Ridker, Ridker, Ridker, Ridker, Ridker, Riveline, Ross, Saito, Sellmayer, Serrano Rios, Simpson, Willerson, Yudkin   +33 more
core   +1 more source